Craft

Edgewise Therapeutics

Stock Price

$34.5

2024-10-29

Market Capitalization

$3.2 B

2024-10-29

Edgewise Therapeutics Summary

Company Summary

Overview
Edgewise Therapeutics is a biotechnology company focused on developing therapies for muscle disorders. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb-girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
Type
Public
Status
Active
Founded
2017
HQ
Boulder, CO, US | view all locations
Website
https://edgewisetx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Kevin Koch

    Kevin Koch, President and Chief Executive Officer, Director

  • Alan Russell

    Alan Russell, Co-Founder and Chief Scientific Officer

  • Laura Brege

    Laura Brege, Director

    • Behrad Derakhshan

      Behrad Derakhshan, Chief Business Officer

    Operating MetricsView all

    Preclinical Phase Projects

    3

    Mar, 2021

    Phase I Projects

    1

    Mar, 2021

    Patent Families

    11

    Mar, 2021

    LocationsView all

    1 location detected

    • Boulder, CO HQ

      United States

      Jennie Smoly Caruthers Biotechnology Building, 3415 Colorado Ave

    Edgewise Therapeutics Financials

    Summary Financials

    Net income (Q1, 2026)
    ($49.0M)
    Cash (Q1, 2026)
    $33.2M
    EBIT (Q1, 2026)
    ($54.1M)
    Enterprise value
    $3.2B

    Footer menu